Provided by Tiger Trade Technology Pte. Ltd.

Warrior Met Coal LLC

97.77
-3.8800-3.82%
Post-market: 97.770.00000.00%18:11 EDT
Volume:665.94K
Turnover:65.50M
Market Cap:5.14B
PE:23.50
High:103.45
Open:102.10
Low:96.00
Close:101.65
52wk High:111.42
52wk Low:57.53
Shares:52.57M
Float Shares:51.78M
Volume Ratio:1.72
T/O Rate:1.29%
Dividend:0.32
Dividend Rate:0.33%
EPS(TTM):4.16
EPS(LYR):1.08
ROE:10.04%
ROA:5.17%
PB:2.24
PE(LYR):90.53

Loading ...

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

GlobeNewswire
·
Jul 20

3 U.S. Manufacturing Stocks Investors Are Watching As Brazil Tariffs Hit

Simply Wall St.
·
Jul 20

Warrior Met Coal Schedules Q2 Earnings Release, Investor Call

Reuters
·
Jul 16

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

GlobeNewswire
·
Jul 14

Blue Creek Completion and Supply Constraints Could Be A Game Changer For Warrior Met Coal (HCC)

Simply Wall St.
·
Jul 12

China Producer Price Pressure Puts Silvercorp Metals And Mining Stocks In Focus

Simply Wall St.
·
Jul 10

HCC Healthcare Signs Business Combination Agreement with RF Acquisition Corp III to Pursue Nasdaq Listing

GlobeNewswire
·
Jul 10

Warrior Met Coal (HCC) Gets a Buy from Jefferies

TIPRANKS
·
Jul 09

RBC Capital Sticks to Their Hold Rating for Warrior Met Coal (HCC)

TIPRANKS
·
Jul 09

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

GlobeNewswire
·
Jul 06

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

GlobeNewswire
·
Jul 01

3 US Manufacturing Stocks Tied To Onshoring And Trade Tariff Shifts

Simply Wall St.
·
Jul 01

Warrior Met Coal is Maintained at Buy by UBS

Dow Jones
·
Jul 01

UBS Adjusts Price Target on Warrior Met Coal to $100 From $102, Maintains Buy Rating

MT Newswires Live
·
Jun 30

UBS Keeps Their Buy Rating on Warrior Met Coal (HCC)

TIPRANKS
·
Jun 30

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

GlobeNewswire
·
Jun 26

HENLIUS Announces First US Patient Dosed in Global Phase 1 Trial for HLX13, an Ipilimumab Biosimilar, in First-Line Unresectable Advanced Liver Cancer

Stock News
·
Jun 25

SQM Stock And 2 Global Exporters For Investors Looking Beyond Tech

Simply Wall St.
·
Jun 24

Warrior Met Coal’s (HCC) Insider Sales Amid Rich Valuation: What Do They Signal About Risk‑Reward?

Simply Wall St.
·
Jun 24

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

GlobeNewswire
·
Jun 22